A Dose Block-randomized, Double-blind, Placebo Controlled, Single-dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of DWP10292 After Oral Administration in Healthy Male Subjects
Latest Information Update: 18 Sep 2019
At a glance
- Drugs DWP 10292 (Primary)
- Indications Retinitis pigmentosa
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
- 23 Apr 2014 New trial record